US11959916B2 - Method, system, and program for supplying immunodynamics-related information - Google Patents

Method, system, and program for supplying immunodynamics-related information Download PDF

Info

Publication number
US11959916B2
US11959916B2 US16/958,167 US201816958167A US11959916B2 US 11959916 B2 US11959916 B2 US 11959916B2 US 201816958167 A US201816958167 A US 201816958167A US 11959916 B2 US11959916 B2 US 11959916B2
Authority
US
United States
Prior art keywords
lymphocyte
cell
objective variable
calculated
act
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US16/958,167
Other languages
English (en)
Other versions
US20210231655A1 (en
Inventor
Tamio Yamauchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of US20210231655A1 publication Critical patent/US20210231655A1/en
Application granted granted Critical
Publication of US11959916B2 publication Critical patent/US11959916B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/557—Immunoassay; Biospecific binding assay; Materials therefor using kinetic measurement, i.e. time rate of progress of an antigen-antibody interaction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B45/00—ICT specially adapted for bioinformatics-related data visualisation, e.g. displaying of maps or networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
    • G16B50/30—Data warehousing; Computing architectures
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/40—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Definitions

  • the present invention relates to a method of supplying immunodynamics-related information.
  • the inventor has previously proposed a method of measuring immunodynamics in blood analysis characterized in measuring antigen recognition function, etc., though the immunocompetent cells that were focused on at that time were not enough to comprehend the entire structure of immunodynamics (Patent Reference 1).
  • Patent Reference 1 JP B 2568136
  • An object of the present invention is to provide immunodynamics-related information that helps an easy comprehension of the immunodynamics of cellular immunity of a subject and can therefore be a guiding principle for therapy and prophylaxis for a disease and/or symptom of the subject.
  • the inventor chose patients with prostate cancer as examples, carried out statistical analyses of cell-counts of immunocompetent cells in subjects' blood, and found out that the cell-counts of immunocompetent cells are associated with prognosis. The inventor further carried on the investigation and found that immunodynamics-related information which helps determination of therapy or prophylaxis for a disease and/or symptom can be obtained by analyzing the cell-counts of immunocompetent cells, and thus completed the invention.
  • the present invention relates to:
  • the discriminant function is obtained by performing a discriminant analysis for a data cluster containing data of the condition of an individual and the cell-count of each of multiple types of immunocompetent cells in blood collected from the individual in a number that allows for the discriminant analysis, wherein the condition of the individual is set an objective variable and the multiple types of immunocompetent cells are set as explanatory variables;
  • the group into which the subject is to be sorted is one of the multiple groups that are divided from the data cluster used for obtaining the discriminant function using discriminant scores as indicator.
  • the standard partial regression coefficients of monocyte, Act.Th1 lymphocyte and Tc*DR lymphocyte are all positive.
  • the standard partial regression coefficients of monocyte, Act.Th2 lymphocyte and CD20*DR lymphocyte are all positive.
  • the standard partial regression coefficients of monocyte, Act.Th1 lymphocyte and Tc*DR lymphocyte are all positive.
  • the standard partial regression coefficients of monocyte, Act.Th2 lymphocyte and CD20*DR lymphocyte are all positive.
  • the discriminant function is obtained by performing a discriminant analysis for a data cluster containing data of the condition of an individual and the cell-count of each of multiple types of immunocompetent cells in blood collected from the individual in a number that allows for the discriminant analysis, wherein the condition of the individual is set an objective variable and the multiple types of immunocompetent cells are set as explanatory variables;
  • the group into which the subject is to be sorted is one of the multiple groups that are divided from the data cluster used for obtaining the discriminant function using discriminant scores as indicator.
  • the discriminant function is obtained by performing a discriminant analysis for a data cluster containing data of the condition of an individual and the cell-count of each of multiple types of immunocompetent cells in blood collected from the individual in a number that allows for the discriminant analysis, wherein the condition of the individual is set an objective variable and the multiple types of immunocompetent cells are set as explanatory variables;
  • the group into which the subject is to be sorted is one of the multiple groups that are divided from the data cluster used for obtaining the discriminant function using discriminant scores as indicator.
  • immunodynamics-related information of a subject can be obtained from cell-counts of immunocompetent cells in blood of the subject.
  • the immunodynamics-related information can be used as a guiding principle for determining therapy or prophylaxis for a disease and/or symptom depending on the immunodynamics of individual subject.
  • immunodynamics of the subject's cellular immunity can easily be comprehended, and immunodynamics-related information can be provided which can be used as guiding principle for diagnosis of a disease and/or symptom of a subject, in particular pathology of diseases such as autoimmune diseases (asthma, atopic dermatoses, etc.), genetic diseases which cause immune disorder, diseases related to immunity against organ transplant, cancerous diseases, infectious diseases, diseases related to cellular immunity, and therapy or prophylaxis for these diseases.
  • autoimmune diseases asthma, atopic dermatoses, etc.
  • genetic diseases which cause immune disorder, diseases related to immunity against organ transplant, cancerous diseases, infectious diseases, diseases related to cellular immunity, and therapy or prophylaxis for these diseases.
  • it can be used for controlling the immunity when using an immunosuppressant, and for monitoring immunodynamics related to acute or chronic rejection caused upon an organ transplant.
  • immunodynamics-related information can be provided for each of the sorted groups. More appropriate information about immunodynamics can be obtained by sorting a subject into a specific group based on cell-count data of the immunocompetent cells obtained from the subject. This can further help determining an appropriate therapy or prophylaxis.
  • FIG. 1 represents survival rate curves of 59 cases each of GOOD, MODERATE and BAD groups (total 177 cases).
  • FIG. 2 represents a scatter plotting of discriminant scores of 177 cases.
  • FIG. 3 represents a scatter plotting of discriminant scores of 162 cases sorted in GOOD group.
  • FIG. 4 represents a scatter plotting of discriminant scores of 45 cases sorted in MODERATE group.
  • FIG. 5 represents scatter plotting of discriminant scores of 137 cases sorted into BAD group.
  • FIG. 41 represents transition of different indices in subjects with lingual cancer.
  • FIG. 42 represents transition of different indices in subjects with prostate cancer.
  • Cultured Living Cell Count indicates the number of lymphocytes that were collected from 40 ml of venous blood drawn from the subject, cultured, and still viable on the day of administering blood transfusion.
  • Peripheral Blood NK Activity is the activity of NK cells collected from peripheral blood of the subject, measured by flow-cytometry using calcein-AM fluorescent staining dye (effector-target ratio; 12:1).
  • Cultured NK Activity (the activity of cultured NK cells) is the activity of NK cells collected from 40 ml of venous blood drawn from the subject and cultured, measured by flow-cytometry using calcein-AM fluorescent staining dye (effector-target ratio; 12:1).
  • Killer Activity is the activity of killer T-cells collected from 40 ml of venous blood drawn from the subject and cultured, measured by flow-cytometry using calcein-AM fluorescent staining dye (effector target ratio; 12:1).
  • Cultured NK Cell Count (the number of cultured NK cells) indicates the number of NK cells that were collected from 40 ml of venous blood drawn from the subject and cultured. Cell counts are given in a unit of *10 7 cells.
  • CD3+CD8- ⁇ -T cell indicates the number of CD3+CD8+ ⁇ -T cells that were collected from 40 ml of venous blood drawn from the subject and cultured. This is a cell fraction which contains killer T-cells and given in a unit of *10 9 cells.
  • CD3+CD4+ ⁇ -T cell indicates the number of CD3+CD4+ ⁇ -T cells that were collected from 40 ml of venous blood drawn from the subject and cultured. This is a cell fraction which contains helper T-cells and given in a unit of *10 7 cells.
  • FIG. 43 represents transition of killer T-cell activity index and killer T-cell ADCC activity index in a subject with prostate cancer.
  • FIG. 44 represents transition of NK-cell activity index and NK-cell ADCC activity index in a subject with prostate cancer.
  • FIG. 45 represents transition of NKT-cell activity index and NKT-cell ADCC activity index in a subject with prostate cancer.
  • FIG. 46 represents a scatter plot of discriminant scores of 267 cases obtained by a discriminant function generated by targeting the 267 cases.
  • the present invention relates to a method for supplying immunodynamics-related information for use in determining therapy or prophylaxis for a disease and/or symptom of a subject.
  • a subject may be any living organism, and is preferably a mammal including, for example, a primate such as human and chimpanzee, a rodent such as mouse, rat, guinea pig and hamster, and cattle, camel, goat, sheep, horse, rabbit, dog and cat, and is more preferably, human.
  • a primate such as human and chimpanzee
  • a rodent such as mouse, rat, guinea pig and hamster
  • cattle camel, goat, sheep, horse, rabbit, dog and cat, and is more preferably, human.
  • a disease and/or symptom is not particularly limited, but, for example, a disease and/or symptom associated with immunity. More specifically, it includes autoimmune diseases (such as asthma, atopic dermatoses, chronic inflammatory demyelinating polyneuropathy/multifocal motor neuropathy), genetic diseases which cause immune disorder, diseases related to immunity against organ transplant, cancerous diseases, infectious diseases, viral diseases related to cellular immunity (such as serum hepatitis), and amyotrophic lateral sclerosis, etc.
  • autoimmune diseases such as asthma, atopic dermatoses, chronic inflammatory demyelinating polyneuropathy/multifocal motor neuropathy
  • genetic diseases which cause immune disorder diseases related to immunity against organ transplant, cancerous diseases, infectious diseases, viral diseases related to cellular immunity (such as serum hepatitis), and amyotrophic lateral sclerosis, etc.
  • An autoimmune disease includes, such as, e.g., asthma, pollinosis, atopic dermatitis, sarcoidosis, Wegener's granulomatous angiitis, collagen disease overlap syndrome, infertility, pernicious anemia, Guillain-Barre syndrome, myasthenia gravis, chronic gastritis, chronic atrophic gastritis, autoimmune hepatitis, primary biliary cholangitis, ulcerative colitis, Crohn's disease, autoimmune pancreatitis, Takayasu's arteritis, Goodpasture's syndrome, rapidly progressive glomerulonephritis, megaloblastic anemia, autoimmune hemolytic anemia, autoimmune neutropenia, idiopathic thrombocytopenic purpura, Graves' disease (Basedow's disease), Hashimoto's disease (chronic thyroiditis), primary hypothyroidism, idiopathic Addison's disease, type 1 diabetes, insulin
  • Cancerous diseases are, for example, cancers and sarcomas including, such as, e.g., brain tumor (such as malignant glioma and glioblastoma), lung cancer (adenocarcinoma, squamous cell carcinoma, large cell carcinoma, small cell carcinoma), mediastinal tumor, head and neck cancer such as nasopharyngeal cancer, laryngeal cancer, lingual cancer, oral (mucosal) cancer and gingival cancer; esophageal cancer, gastric cancer, colorectal cancer, rectal cancer, anal cancer, liver cancer (including those originated from hepatic cirrhosis due to hepatitis B or C or other alcoholic or lipogenous hepatic cirrhosis), cancer of gastrointestinal system such as gallbladder/bile duct cancer, pancreatic cancer; gynecologic cancer such as breast cancer, cervical cancer, uterine body cancer, ovarian cancer and endometrial cancer; urogen
  • Infectious diseases include, such as, e.g., viral infection, bacterial infection, fungal infection, protozoan parasite infection and helminthic parasite infection.
  • Viral infections include, such as, e.g., common cold, norovirus infection, rotavirus infection, influenza virus infection, viral hepatitis, viral meningitis, acquired immunodeficiency syndrome (AIDS), adult T-cell leukemia, Ebola hemorrhagic fever, yellow fever, common cold syndrome, rabies, cytomegalovirus infection, severe acute respiratory syndrome (SARS), progressive multifocal leukoencephalopathy, chickenpox/herpes zoster, herpes simplex, hand-foot-and-mouth disease, dengue fever, erythema infectiosum, infectious mononucleosis, smallpox, rubella, acute anterior poliomyelitis (polio), measles, pharyngoconjunctival fever (pool fever), Marburg hemorrhagic fever, hantavirus renal hemorrhagic fever, Lassa fever, South American hemorrhagic fever, Middle East respiratory syndrome (MERS), m
  • Bacterial infection include a variety of infections by, such as, e.g., Streptococcus (e.g., Group A ⁇ hemolytic streptococcus, Streptococcus pneumoniae ), Staphylococcus aureus (MSSA, MRSA), Staphylococcus epidermidis, Enterococcus, Listeria, Neisseria meningitidis, Neisseria gonorrhoeae, pathogenic Escherichia coil (e.g., O157:H7), Klebsiella ( Klebsiella pneumoniae ), Proteus, Bordetella pertussis, Pseudomonas aeruginosa, Serratia, Citrobacter, Acinetobacter, Enterobacter, Mycoplasma, Clostridium, and tuberculosis, cholera, plague, diphtheria, dysentery, scarlet fever, anthrax, syphilis, tetanus, Hans
  • therapy can be any therapy known for the disease or symptom, and may be, without being particularly limited, for example, a therapy that utilizes immune function such as immune checkpoint inhibitor therapy, cytokine therapy, cell adoptive immunity therapy (e.g., ⁇ T cell, ⁇ T cell, NK cell and NKT cell), regenerative immunotherapy with IPS cells and genetically modified T cell therapy (CAR-T: Chimeric Antigen Receptor T-cell Therapy).
  • a therapy that utilizes immune function such as immune checkpoint inhibitor therapy, cytokine therapy, cell adoptive immunity therapy (e.g., ⁇ T cell, ⁇ T cell, NK cell and NKT cell), regenerative immunotherapy with IPS cells and genetically modified T cell therapy (CAR-T: Chimeric Antigen Receptor T-cell Therapy).
  • prophylaxis can be any prophylaxis known for the disease or symptom, and may be, without being particularly limited, for example, a prophylaxis that enhances immune function by an intake or administration of an useful substance.
  • the useful substances include, for example, fungus such as Agaricus, Reishi, Polyporaceae (Hoelen), Cordyceps, Shiitake mushroom, Shiitake mushroom extract, AHCC (Active Hexose Correlated Compound)® or a functional food, extract or supplement made of fungus; Chinese herbal medicines such as juzen-taiho-to, harnessu-ekki-to and sairei-to; lipid-lowering drug; supplements such as vitamins such as vitamin D3.
  • immunodynamics-related information is information for determining whether different immunocompetent cells are coordinately functioning or whether their differentiation and proliferation is stagnated/inhibited, and it means, for example, information about analyses of the degree or condition of the correlation between different immunocompetent cells.
  • immunodynamics-related information can be expressed as an immunodynamics chart. By being expressed as an immunodynamics chart, the condition of immunodynamics will more easily be determined or understood. Such information is extremely useful in determining the immunocompetent cell to be targeted or the correlation between immunocompetent cells for therapy or prophylaxis of a disease or symptom.
  • the degree of coordination is expressed, for example, by a influence degree (the area of a circle in an immunodynamics chart) or by either positive or negative value of the partial regression coefficient (a type of arrow in the immunodynamics chart).
  • the method for supplying immunodynamics-related information of the present invention comprises:
  • the discriminant function can be obtained by performing a discriminant analysis for a data cluster containing data of the condition of an individual and the cell-count of each of multiple types of immunocompetent cells in blood collected from the individual in a number that allows for the discriminant analysis, wherein the condition of the individual is set as an objective variable, and the multiple types of immunocompetent cells are set as explanatory variables.
  • the condition of an individual is such as, e.g., health, a disease, a disorder, a symptom or prognosis of an individual.
  • the condition of an individual can be typified according to the necessity. It is typified, for example, by degree of health, degree of symptoms, type or degree of the disease, type or degree of the disorder, and degree of the prognosis. Typification can also be, for example, classification by the values of biomarkers, by disease stages, by the rate of complete remission, by survival rate such as three-year or five-year survival rate.
  • the number of individuals is any number.
  • a plurality of data can be obtained from one individual.
  • the group into which the subject is to be sorted is one of the multiple groups that are divided from the data cluster used for obtaining the discriminant function using discriminant scores as indicator.
  • a discriminant analysis encompasses a discriminant analysis which involves two groups of objective variables, as well as a multiple discriminant analysis or canonical discriminant analysis which involves three or more groups of objective variables.
  • a data cluster means a cluster of data which comprises at least data of the condition of an individual and data of the cell-counts of multiple immunocompetent cells in blood collected from the individual, and the data cluster comprises such data in a number that allows for the discriminant analysis.
  • the number that allows for the discriminant analysis is a number which exceeds the number of explanatory variables by at least one in the discriminant analysis.
  • the data cluster can be divided into multiple groups using the discriminant score as an indicator.
  • an immunocompetent cell means any cell which is in charge of immune response, and includes, such as, without being particularly limited, e.g., a leukocyte, monocyte, basophil, eosinophil, neutrophil, CD3-positive lymphocyte (CD3), CD4-positive lymphocyte (CD4), CD8-positive lymphocyte (CD8), CD20*DR lymphocyte (CD20*DR), Ti lymphocyte (inducer T cell; Ti), Ti ⁇ 2 lymphocyte (Ti ⁇ 2), Ti ⁇ lymphocyte (Ti ⁇ ), Ti+2 lymphocyte (Ti+2), Th lymphocyte (helper T cell; Th), Th1 lymphocyte (helper Th1 lymphocyte; helper Th1 cell; Th1), Th2 lymphocyte (helper Th2 lymphocyte; helper Th2 cell; Th2), Th ⁇ 2 lymphocyte (Th ⁇ 2), Th ⁇ lymphocyte (Th ⁇ ), Th+2 lymphocyte (Th+2), Th17+ lymphocyte (Th17+), Ts lymphocyte (suppressor T cell; Ts), Ts ⁇ lymphocyte (inducer
  • the cell-count of an immunocompetent cell can be counted or calculated according to a conventional method.
  • the number of leukocytes, lymphocytes, monocyte, basophil, eosinophils or neutrophils can be counted to I digit of real number by subjecting the blood drawn from the subject to a general automatic hemocyte counting apparatus.
  • Lymphocytes are single- or multi-stained for the abundance ratio of various cell-surface markers such as, e.g., CD3, CD4, CD8, CD11b, CD16, CD20, CD25, CD45RA, CD56, CD122, CD161, FoxP3, HLA-DR, IFN ⁇ and IL-4 using antibodies, and measured by flow-cytometry.
  • cell-surface markers such as, e.g., CD3, CD4, CD8, CD11b, CD16, CD20, CD25, CD45RA, CD56, CD122, CD161, FoxP3, HLA-DR, IFN ⁇ and IL-4 using antibodies, and measured by flow-cytometry.
  • lymphocytes are defined as described below by the combination of various cell-surface markers such as, e.g., CD3, CD4, CD8, CD11b, CD16, CD20, CD25, CD45RA, CD56, CD122, CD161, FoxP3, HLA-DR, IFN ⁇ and IL-4.
  • cell-surface markers such as, e.g., CD3, CD4, CD8, CD11b, CD16, CD20, CD25, CD45RA, CD56, CD122, CD161, FoxP3, HLA-DR, IFN ⁇ and IL-4.
  • a CD3-positive lymphocyte means a lymphocyte which is CD3-positive. This is similar for representation such as a CD4-positive or CD8-positive lymphocyte.
  • the number of CD3-positive lymphocytes can be calculated, for example, by multiplying either the percentage of CD3-positives in the result of a double-staining flow-cytometry analysis for CD3 and CD161 (i.e., the sum of the percentage of [CD3-positive and CD161-negative] plus the percentage of [CD3-positive and CD161-positive]) or the percentage of CD3-positives in the result of a quadruple-staining flow-cytometry analysis for CD11b, CD122, CD3 and CD8 by the number of lymphocytes. For instance, the values of these may be compared to adopt smaller value.
  • the number of CD4-positive lymphocytes can be calculated, for example, by using either of the percentage of CD4-positives in the result of a double-staining flow-cytometry analysis for HLA-DR and CD4 (i.e., the sum of the percentage of [CD4-positive and KA-DR-negative] and the percentage of [CD4-positive and HLA-DR-positive]) or the percentage of CD4-positives in the result of a quadruple-staining flow-cytometry analysis for CD45RA, FoxP3, CD4 and CD25, and multiplying this by the number of lymphocytes. For instance, the values of these may be compared to adopt smaller value.
  • the number of CD8-positive lymphocytes can be calculated, for example, by multiplying the percentage of CD8-positives in the result of a double-staining flow-cytometry analysis for HLA-DR and CD8 (i.e., the sum of the percentage of [CD8-positive and HLA-DR-negative] and the percentage of [CD8-positive and HLA-DR-positive]) by the number of lymphocytes.
  • CD20*DR lymphocyte means a lymphocyte that is CD20-positive and HLA-DR-positive.
  • the number of CD20*DR lymphocytes can be calculated, for example, by multiplying the percentage of [CD20-positive and HLA-DR-positive] in the result of a double-staining flow-cytometry analysis for HLA-DR and CD20 by the number of lymphocytes.
  • Ti lymphocyte means a lymphocyte that is CD4-positive and CD45RA-positive.
  • the number of Ti lymphocytes can be calculated, for example, by multiplying the percentage of [CD4-positive and CD45RA-positive] in the result of a quadruple-staining flow-cytometry analysis for CD45RA, FoxP3, CD4 and CD25 by the number of lymphocytes.
  • Ti ⁇ 2 lymphocyte means a lymphocyte that is CD4-positive, CD45RA-positive, CD25-negative, and FoxP3-negative.
  • the number of Ti ⁇ 2 lymphocytes can be calculated, for example, by multiplying the percentage of [CD4-positive and CD45RA-positive] and the percentage of [CD4-positive, CD45RA-positive, CD25-negative and FoxP3-negative] in the result of a quadruple-staining flow-cytometry analysis for CD45RA, FoxP3, CD4 and CD25, and multiplying this by the number of lymphocytes.
  • Ti ⁇ lymphocyte means a lymphocyte that is CD4-positive, CD45RA-positive, CD25-positive, and FoxP3-negative.
  • the number of Ti ⁇ lymphocytes can be calculated, for example, by multiplying the percentage of [CD4-positive and CD45RA-positive] and the percentage of [CD4-positive, CD45RA-positive, CD25-positive and FoxP3-negative] in the result of a quadruple-staining flow-cytometry analysis for CD45RA, FoxP3, CD4 and CD25, and multiplying this by the number of lymphocytes.
  • Ti+2 lymphocyte means a lymphocyte that is CD4-positive, CD45RA-positive, CD25-positive, and FoxP3-positive.
  • the number of Ti+2 lymphocytes can be calculated, for example, by multiplying the percentage of [CD4-positive and CD45RA-positive] and the percentage of [CD4-positive, CD45RA-positive, CD25-positive and FoxP3-positive] in the result of a quadruple-staining flow-cytometry analysis for CD45RA, FoxP3, CD4 and CD25, and multiplying this by the number of lymphocytes.
  • Th lymphocyte means a lymphocyte that is CD4-positive, and CD45RA-negative.
  • the number of Th lymphocytes can be calculated, for example, by multiplying the percentage of [CD4-positive and CD45RA-negative] in the result of a quadruple-staining flow-cytometry analysis for CD45RA, FoxP3, CD4 and CD25 by the number of lymphocytes.
  • Th1 lymphocyte means a lymphocyte that is CD4-positive, CD45RA-negative, IFN ⁇ -positive, and IL-4-negative.
  • the number of Th1 lymphocytes can be calculated by multiplying the number of Th lymphocytes by, e.g., the percentage of [CD4-positive, IFN ⁇ -positive and IL-4-negative] in the results of triple staining analysis by flow-cytometry for CD4, IFN ⁇ and IL-4.
  • Th2 lymphocyte means a lymphocyte that is CD4-positive, CD45RA-negative, IFN ⁇ -negative, and IL-4-positive.
  • the number of Th2 lymphocytes can be calculated, for example, by multiplying the number of Th lymphocytes by the percentage of [CD4-positive, IFN ⁇ -negative and IL-4-positive] in the results of triple staining analysis by flow-cytometry for CD4, IFN ⁇ and IL-4.
  • Th ⁇ 2 lymphocyte means a lymphocyte that is CD4-positive, CD45RA-negative, CD25-negative, and FoxP3-negative.
  • the number of Th ⁇ 2 lymphocytes can be calculated, for example, by multiplying the percentage of [CD4-positive and CD45RA-negative] and the percentage of [CD4-positive, CD45RA-negative, CD25-negative and FoxP3-negative] in the result of a quadruple-staining flow-cytometry analysis for CD45RA, FoxP3, CD4 and CD25, and multiplying this by the number of lymphocytes.
  • Th ⁇ lymphocyte means a lymphocyte that is CD4-positive, CD45RA-negative, CD25-positive, and FoxP3-negative.
  • the number of Th ⁇ lymphocytes can be calculated, for example, by multiplying the percentage of [CD4-positive and CD45RA-negative] and the percentage of [CD4-positive, CD45RA-negative, CD25-positive and FoxP3-negative] in the result of a quadruple staining flow-cytometry analysis for CD45RA, FoxP3, CD4 and CD25, and multiplying this by the number of lymphocytes.
  • Th+2 lymphocyte means a lymphocyte that is CD4-positive, CD45RA-negative, CD25-positive, and FoxP3-positive.
  • the number of Th+2 lymphocytes can be calculated, for example, by multiplying the percentage of [CD4-positive and CD45RA-negative] and the percentage of [CD4-positive, CD45RA-negative, CD25-positive and FoxP3-positive] in the result of a quadruple-staining flow-cytometry analysis for CD45RA, FoxP3, CD4 and CD25, and multiplying this by the number of lymphocytes.
  • Th17+ lymphocyte means a lymphocyte that is CD4-positive, IFN ⁇ -positive and IL-17-positive.
  • the number of Th17+ lymphocytes can be calculated, for example, by multiplying the percentage of [IFN ⁇ -positive and IL-17-positive] in the results of triple staining analysis by flow-cytometry for IFN ⁇ , CD4 and IL-17 by the number of CD4 lymphocytes.
  • Act.i/h T lymphocytes means a lymphocyte that is CD4-positive and HLA-DR-positive.
  • the number of Act.i/h T lymphocytes can be calculated, for example, by multiplying the percentage of [CD4-positive and HLA-DR-positive] in the result of a double-staining flow-cytometry analysis for HLA-DR and CD4 by the number of lymphocytes.
  • the number of Ti*DR lymphocytes (Activated inducer T cell) can be calculated, for example, by multiplying Act.i/h T lymphocytes and the number of Ti lymphocytes/(the number of Th lymphocytes+the number of Ti lymphocytes).
  • the number of Th*DR lymphocytes (Activated helper T cells) can be calculated, for example, by multiplying the number of Act.i/h T lymphocytes by [the number of Th lymphocytes ⁇ (the number of Th lymphocytes+the number of Ti lymphocytes)].
  • the number of Act.Th1 lymphocytes can be calculated, for example, by multiplying the number of Th*DR lymphocytes by [the number of TH1 lymphocytes ⁇ (the number of Th1 lymphocytes+the number of Th2 lymphocytes)].
  • the number of Act.Th2 lymphocytes can be calculated, for example, by multiplying the number of Th*DR lymphocytes by [the number of Th2 lymphocytes ⁇ (the number of Th1 lymphocytes+the number of Th2 lymphocytes)].
  • Ts lymphocyte (Suppressor T cell) means a lymphocyte that is CD8-positive and CD11b-positive.
  • the number of Ts lymphocytes can be calculated, for example, by multiplying the percentage of [CD8-positive and CD11 b-positive] in the result of a quadruple-staining flow-cytometry analysis for CD11b, CD122, CD3 and CD8 by the number of lymphocytes.
  • Ts ⁇ lymphocyte means a lymphocyte that is CD8-positive, CD11b-positive and CD122-negative.
  • the number of Ts ⁇ lymphocytes can be calculated, for example, by multiplying the percentage of [CD8-positive and CD11b-positive] and the percentage of [CD11b-positive and CD122-negative] in the result of a quadruple-staining flow-cytometry analysis for CD11b, CD122, CD3 and CD8, and multiplying this by the number of lymphocytes.
  • Ts+ lymphocyte means a lymphocyte that is CD8-positive, CD11b-positive and CD122-positive.
  • the number of Ts+ lymphocytes can be calculated, for example, by multiplying the percentage of [CD8-positive and CD11b-positive] and the percentage of [CD11b-positive and CD122-positive] in the result of a quadruple-staining flow-cytometry analysis for CD11b, CD122, CD3 and CD8, and multiplying this by the number of lymphocytes.
  • Tc lymphocyte (Cytotoxic T cell) means a lymphocyte that is CD8-positive and CD11b-negative.
  • the number of Tc lymphocytes can be calculated, for example, by multiplying the percentage of [CD8-positive and CD11b-negative] in the result of a quadruple-staining flow-cytometry analysis for CD11b, CD122, CD3 and CD8 by the number of lymphocytes.
  • Tc ⁇ lymphocyte means a lymphocyte that is CD8-positive, CD11b-negative, and CD122-negative.
  • the number of Tc ⁇ lymphocytes can be calculated, for example, by multiplying the percentage of [CD8-positive and CD11b-negative] and the percentage of [CD11b-negative and CD122-negative] in the result of a quadruple-staining flow-cytometry analysis for CD11b, CD122, CD3 and CD8, and multiplying this by the number of lymphocytes.
  • Tc+ lymphocyte means a lymphocyte that is CD8-positive, CD11b-negative, and CD122-positive.
  • the number of Tc+ lymphocytes can be calculated, for example, by multiplying the percentage of [CD8-positive and CD11b-negative] and the percentage of [CD11b-negative and CD122-positive] in the result of a quadruple-staining flow-cytometry analysis for CD11b, CD122, CD3 and CD8, and multiplying this and the number of lymphocytes.
  • the number of Act.s/cT lymphocytes can be calculated, for example, by multiplying the percentage of [CD8-positive and HLA-DR-positive] in the result of a double-staining flow-cytometry analysis for HLA-DR and CD8 by the number of lymphocytes.
  • the number of Ts*DR lymphocytes (Activated suppressor T Cells) can be calculated, for example, by multiplying the number of Act.s/cT lymphocytes by [the number of Ts lymphocytes ⁇ (the number of Tc lymphocytes+the number of Ts lymphocytes)].
  • the number of Tc*DR lymphocytes (Activated cytotoxic T cells) can be calculated, for example, by multiplying the number of Act.s/cT lymphocytes by [the number of To lymphocytes ⁇ (the number of Tc lymphocytes+the number of Ts lymphocytes)].
  • NK cell Natural killer Cell means a lymphocyte that is CD16-positive and CD56-positive.
  • the number of NK cells can be calculated, for example, by multiplying the percentage of [CD16-positive and CD56-positive] in the results of triple staining analysis by flow-cytometry for CD16, CD161 and CD56 by the number of lymphocytes.
  • NKT cells Natural killer T cell means a lymphocyte that is CD3-positive and CD161-positive.
  • the number of NKT cells can be calculated, for example, by multiplying the percentage of [CD3-positive and CD161-positive] in the result of a double-staining flow-cytometry analysis for CD3 and CD161 by the number of lymphocytes.
  • N3+ cell means a lymphocyte that is CD16-positive, CD161-positive and CD56-positive.
  • the number of N3+ cell can be calculated, for example, by multiplying the percentage of [CD16-positive, CD161-positive and CD56-positive] in the results of triple staining analysis by flow-cytometry for CD16, CD161 and CD56 by the number of lymphocytes.
  • the multiple types of immunocompetent cells are three or more selected from a group consisting of, e.g., Th17+ lymphocyte, CD3-positive lymphocyte, CD4-positive lymphocyte, CD8-positive lymphocyte, CD20*DR lymphocyte, Th ⁇ lymphocyte, Th ⁇ 2 lymphocyte, Th+2 lymphocyte, Act.Th1 lymphocyte, Act.Th2 lymphocyte, Ti*DR lymphocyte, Ti ⁇ lymphocyte, Ti ⁇ 2 lymphocyte, Ti+2 lymphocyte, Tc*DR lymphocyte, Tc ⁇ lymphocyte, Tc+ lymphocyte, Ts*DR lymphocyte, Ts ⁇ lymphocyte, Ts+ lymphocyte, NK cell, NKT cell, N3+ cell, monocyte, basophil, eosinophils, neutrophil, Th1 lymphocyte, Th2 lymphocyte, Ti lymphocyte, Tc lymphocyte, Ts lymphocyte, Act.i/h T lymphocytes and Act.s/cT lymphocyte.
  • the multiple types of immunocompetent cells are three or more selected from a group consisting of, e.g., Th17+ lymphocyte, CD3-positive lymphocyte, CD4-positive lymphocyte, CD8-positive lymphocyte, CD20*DR lymphocyte, Th ⁇ lymphocyte, Th ⁇ 2 lymphocyte, Th+2 lymphocyte, Act.Th1 lymphocyte, Act.Th2 lymphocyte, Ti*DR lymphocyte, Ti ⁇ lymphocyte, Ti ⁇ 2 lymphocyte, Ti+2 lymphocyte, Tc*DR lymphocyte, Tc ⁇ lymphocyte, Tc+ lymphocyte, Ts*DR lymphocyte, Ts ⁇ lymphocyte, Ts+ lymphocyte, NK cell, NKT cell, N3+cell, monocyte, basophil, eosinophil and neutrophil.
  • the multiple types of immunocompetent cells comprise, e.g., Th17+ lymphocyte.
  • the multiple types of immunocompetent cells are 17 types consisting of: CD3-positive lymphocyte, CD4-positive lymphocyte, CD8-positive lymphocyte, CD20*DR lymphocyte, Th1 lymphocyte, Th2 lymphocyte, Ti lymphocyte, Tc lymphocyte, Ts lymphocyte, Act.i/h T lymphocyte, Act.s/c T lymphocyte, NK cell, N3+cell, monocyte, basophil, eosinophil and neutrophil.
  • the multiple types of immunocompetent cells are 26 types consisting of: CD3-positive lymphocyte, CD4-positive lymphocyte, CD8-positive lymphocyte, CD20*DR lymphocyte, Th ⁇ lymphocyte, Th ⁇ 2 lymphocyte, Th+2 lymphocyte, Act.Th1 lymphocyte, Act.Th2 lymphocyte, Ti*DR lymphocyte, Ti ⁇ lymphocyte, Ti ⁇ 2 lymphocyte, Ti+2 lymphocyte, Tc*DR lymphocyte, Tc ⁇ lymphocyte, Tc+ lymphocyte, Ts*DR lymphocyte, Ts ⁇ lymphocyte, Ts+ lymphocyte, NK cell, NKT cell, N3+ cell, monocyte, basophil, eosinophil and neutrophil.
  • the multiple types of immunocompetent cells are 27 types consisting of: Th17+ lymphocyte, CD3-positive lymphocyte, CD4-positive lymphocyte, CD8-positive lymphocyte, CD20*DR lymphocyte, Th- ⁇ lymphocyte, Th ⁇ 2 lymphocyte, Th+2 lymphocyte, Act.Th1 lymphocyte, Act.Th2 lymphocyte, Ti*DR lymphocyte, Ti ⁇ lymphocyte, Ti ⁇ 2 lymphocyte, Ti+2 lymphocyte, Tc*DR lymphocyte, Tc ⁇ lymphocyte, Tc+ lymphocyte, Ts*DR lymphocyte, Ts ⁇ lymphocyte, Ts+ lymphocyte, NK cell, NKT cell, N3+ cell, monocyte, basophil, eosinophil and neutrophil.
  • immunodynamics-related information is obtained, for example, by the following (a) to (d), without being particularly limited:
  • regression analysis not only encompasses a single regression analysis which involves one explanatory variable, but also encompasses a multiple regression analysis which involves two or more explanatory variables.
  • the description “performing multiple regression analyses repeatedly” may include embodiments in which the repeated regression analyses include a single regression analysis which involves one explanatory variable.
  • a constant term when performing a multiple regression analysis, a constant term may or may not be provided.
  • no constant term when performing a multiple regression analysis, no constant term is provided.
  • immunodynamics-related information can be obtained by performing regression analysis as described above on data of cell-counts of n types of immunocompetent cells which constitute the desired group.
  • the one type of immunocompetent cell that is set as the objective variable in (a) above can be selected from a group consisting of, e.g., Tc*DR lymphocyte, CD20*DR lymphocyte, NK cell, NKT cell, basophil, eosinophil and neutrophil.
  • the present invention in one aspect, relates to a system for supplying immunodynamics-related information for use in determining therapy or prophylaxis for a disease and/or symptom of a subject.
  • the system comprises, for example:
  • the discriminant function is obtained by performing a discriminant analysis for a data cluster containing data of the condition of an individual and the cell-count of each of multiple types of immunocompetent cells in blood collected from the individual in a number that allows for the discriminant analysis, wherein the condition of the individual is set an objective variable and the multiple types of immunocompetent cells are set as explanatory variables;
  • the group into which the subject is to be sorted is one of the multiple groups that are divided from the data cluster used for obtaining the discriminant function using discriminant scores as indicator.
  • the present invention in one aspect, relates to a program to be run by a computer for supplying immunodynamics-related information for use in determining therapy or prophylaxis for a disease and/or symptom of a subject.
  • the program comprises, for example:
  • the discriminant function is obtained by performing a discriminant analysis for a data cluster containing data of the condition of an individual and the cell-count of each of multiple types of immunocompetent cells in blood collected from the individual in a number that allows for the discriminant analysis, wherein the condition of the individual is set an objective variable and the multiple types of immunocompetent cells are set as explanatory variables;
  • the group into which the subject is to be sorted is one of the multiple groups that are divided from the data cluster used for obtaining the discriminant function using discriminant scores as indicator.
  • immunodynamics-related information can be provided as an immunodynamics chart.
  • an immunodynamics chart By representing in an immunodynamics chart, the immunodynamics can generally be understood and evaluated.
  • an immunodynamics chart can be generated based on immunodynamics-related information, for example, influence degrees of different immunocompetent cells.
  • examples include the immunodynamics charts shown in FIGS. 6 - 40 .
  • the arrangement of various immunocompetent cells and arrows has been determined based on the process of differentiation and maturation of the immunocompetent cells and their interrelationships.
  • the area of a circle indicating an immunocompetent cell can be made proportional to the percentage (%) of the influence degree of the immunocompetent cell. Moreover, when the percentage of the influence degree (%) of immunocompetent cell is less than 0.00785%, the immunocompetent cell can be represented by X and when the percentage of the influence degree (%) of immunocompetent cell is or more 0.00785% and less than 0.0314%, the immunocompetent cell can be represented by ⁇ .
  • the line weight of the enclosing line can be made 1.0 pt when the percentage of the influence degree (%) of a immunocompetent cell is less than 0.5%; 1.5 pt when the percentage of the influence degree (%) of a immunocompetent cell is 0.5% or more and less than 1%; 2.5 pt when the percentage of the influence degree (%) of a immunocompetent cell is 1% or more and less than 5%; and 3.0 pt when the percentage of the influence degree (%) of a immunocompetent cell is 5% or more.
  • Types of arrows and their meanings are as described in Table 1.
  • the type of an arrow is determined by the interrelationship of immunocompetent cells (a relationship on the differentiation pathway, or a suppressing, facilitating or interacting relationship) and by whether the partial regression coefficient value of the immunocompetent cell obtained by the multiple regression analysis is either positive or negative.
  • an immunocompetent cell used as objective variable i.e., Tc*DR lymphocyte, CD20*DR lymphocyte, NK cell, NKT cell, basophil, eosinophil or neutrophil
  • the relationship is active and an open white arrow will be applied.
  • the partial regression coefficient is negative, the relationship is inactive and a closed black arrow will be applied.
  • CD20*DR lymphocyte is in active or inactive interrelationship with Tc*DR; in an immunodynamics chart directed to NK cell, Tc*DR lymphocyte, CD20*DR lymphocyte and Ti*DR lymphocyte are in active or inactive interrelationships with NK cell; in an immunodynamics chart directed to NKT cell, Tc*DR lymphocyte, CD20*DR lymphocyte and N3+ cell are in active or inactive interrelationships with NKT cell; in an immunodynamics chart directed to CD20*DR lymphocyte, Tc*DR lymphocyte is in active or inactive interrelationship with CD20*DR lymphocyte; in an immunodynamics chart directed to basophil, Tc*DR lymphocyte and Act.Th2 lymphocyte are in active or inactive interrelationships with basophil; in an immunodynamics chart directed to eosinophil, Tc*DR lymphocyte and CD20*DR lymphocyte are active or inactive interrelationships with eosinophils; in an immunodynamics chart directed to eosinophil
  • the line width of an arrow can be 6 pt when the percentage of the influence degree (%) of a immunocompetent cell is less than 0.1%; 8 pt when the percentage of the influence degree (%) of a immunocompetent cell is or more 0.1% and less than 0.5%; 10 pt when the percentage of the influence degree (%) of a immunocompetent cell is 0.5% or more and less than 1.0%; 12 pt when the percentage of the influence degree (%) of a immunocompetent cell is 1.0% or more and less than 5.0%; and 14 pt when the percentage of the influence degree (%) of a immunocompetent cell is 5.0% or more.
  • TARM T-cellular Antigen Recognition Mechanism
  • BARM B-cellular Antigen Recognition Mechanism
  • immunodynamics-related information can be used to calculate, e.g., NK activity index (NK Cell Activity Index: NK-AI), ADCC activity index of NK (NK Cell Antibody Dependent Cellular Cytotoxicity Activity Index: NK-ADCC-AI), NKT activity index (NKT Cell Activity Index: NKT-AI), ADCC activity index of NKT (NKT Cell Antibody Dependent Cellular Cytotoxicity Activity Index: NKT-ADCC-AI), killer T-cell activity index (Activated Cytotoxic T Cell Activity index) (Killer T Cell Activity Index: Killer-AI), killer T-cell ADCC activity index (Killer T Cell Antibody Dependent Cellular Cytotoxicity Activity Index: Killer-ADCC-AI).
  • NK activity index NK Cell Activity Index: NK-AI
  • ADCC activity index of NK NK Cell Antibody Dependent Cellular Cytotoxicity Activity Index: NK-ADCC-AI
  • NKT activity index NKT activity index
  • ADCC activity index of NKT NKT Cell Antibody Dependent Cellular Cytotoxicity Activity Index:
  • contribution ratio in the regression analysis in which NK cell is set as objective variable and all other immunocompetent cells are set as explanatory variables is equal to the sum of respective influence degrees of all immunocompetent cells when the influence degrees are calculated using NK cell as the objective variable.
  • contribution ratio in the regression analysis in which NKT cells is set as objective variable and all other immunocompetent cells are set as explanatory variables is equal to the sum of respective influence degrees of all immunocompetent cells when the influence degrees are calculated using NKT cells as the objective variable.
  • contribution ratio in the regression analysis in which Tc*DR lymphocyte is set as objective variable and all other immunocompetent cells are set as explanatory variables is equal to the sum of respective influence degrees of all immunocompetent cells when the influence degrees are calculated using Tc*DR lymphocyte as the objective variable.
  • NK cell is set as the objective variable
  • T-cellular antigen recognition mechanism TARM
  • BARM B-cellular Antigen Recognition Mechanism
  • NKT cell is set as the objective variable
  • T-cellular antigen recognition mechanism TARM
  • B-cellular Antigen Recognition Mechanism BARM
  • Tc*DR cell is set as the objective variable
  • Tc*DR cell if the standard partial regression coefficient of monocyte, Act.Th1 lymphocyte or Tc*DR lymphocyte is negative, T-cellular antigen recognition mechanism (TARM) is yet to be established and therefore a killer T-cell activity index cannot be calculated.
  • Tc*DR cell is set as the objective variable
  • B-cellular Antigen Recognition Mechanism B-cellular Antigen Recognition Mechanism: BARM
  • Subjects consist of 177 cases undergoing hospital treatment for prostate cancer at various stages and levels of malignancy before treatment. Various treatments were given including hormonal therapy, radical operation and transurethral resection of prostate, etc.
  • the numbers of monocytes, basophils, eosinophils and neutrophils, and the abundance ratio of different markers in different lymphocytes as well as PSA values were measured.
  • the measurement was carried out by SRL, Inc. by request.
  • a multiple regression analysis was performed using PSA value as objective variable, and 17 types: CD3-positive lymphocyte, CD4-positive lymphocyte, CD8-positive lymphocyte, CD20*DR lymphocyte, Th1 lymphocyte, Th2 lymphocyte, Ti lymphocyte, Tc lymphocyte, Ts lymphocyte, Act.i/h T lymphocyte, Act.s/c T lymphocyte, NK cell, N3+ cell, monocyte, basophil, eosinophil and neutrophil as explanatory variables. Then, each expected value was subtracted from respective observed value to give a residual value, which was sorted in ascending order and divided into 3 groups containing 59 cases each, which were sorted into: GOOD group with low residual values; MODERATE group with middle residual values; and BAD group with high residual values.
  • MODERATE group Age between 53 and 90, median 72 years old. PSA value (ng/ml) between 0.1 and 426.92, median 11.54. Stages of advance: A2: 2 cases, B1: 11 cases, B2: 8 cases, C: 24 cases, D1: 5 cases, D2: 9 cases. Malignancy between 3 and 9, median 6. Following-up between 118 and 2,305 days, median 745 days.
  • BAD group Age between 51 and 89, median 71 years old. PSA value (ng/ml) between 0.983 and 6745, median 44.32. Stages of advance: A1: 4 cases, B1: 8 cases, B2: 4 cases, C: 16 cases, D1: 5 cases, D2: 23 cases. Malignancy between 3 and 10, median 7. Following-up between 1 and 6308 days, median 901 days.
  • the survival rate curves of GOOD, MODERATE and BAD groups (59 cases each, total 177 cases) are shown in FIG. 1 . Sorting into groups by the residual values was correlated with the survival rate.
  • a discriminant analysis was performed, in which three groups of GOOD, MODERATE and BAD groups were set as objective variables and 17 types of immunocompetent cells: CD3-positive lymphocyte, CD4-positive lymphocyte, CD8-positive lymphocyte, CD20*DR lymphocyte, Th1 lymphocyte, Th2 lymphocyte, Ti lymphocyte, Tc lymphocyte, Ts lymphocyte, Act.i/h Tlymphocyte, Act.s/c T lymphocyte, NK cell, N3+ cell, monocyte, basophil, eosinophil and neutrophil were set as explanatory variables, to give discriminant functions.
  • the scatter plotting of discriminant scores plotted with first discriminant function values on X-axis and second discriminant function values on Y-axis is shown in FIG. 2 .
  • the discrimination accuracy rate was 71.8%.
  • Three hundred and forty-four blood samples in total were collected from 66 subjects including 23 healthy individuals and 43 patients, and analyzed.
  • Male/female ratio was 43:23, and the age was between 35 and 81 years old, median 65, mean ⁇ S.D. 65.39 ⁇ 7.70 years old. The number of measurements was between once and 47 times, the median was twice, and the mean ⁇ S.D. was 5.2 ⁇ 7.2 times. Healthy individuals are at the age between 44 and 73 years old, the median 60, the mean ⁇ S.D. 59.21 ⁇ 4.98 years old.
  • the male/female ratio was 15/8, the number of measurements was between once and 12 times, the median was twice, and the mean ⁇ S.D. was 3.13 ⁇ 3.21 times. Cases for patients were as described in Table 2. A patient who had complication of gastric cancer and bladder cancer was recorded in duplicate.
  • 1 Renal cancer 2 Molecular targeted therapy for metastasis; exacerbated.
  • the numbers of monocytes, basophils, eosinophils and neutrophils, as well as the abundance ratios of different markers in different lymphocytes were measured by SRL, Inc. by request.
  • the discriminant scores were calculated by assigning cell-counts of immunocompetent cells into the discriminant functions obtained in Example 2, and each case was sorted into a group the center of which was the closest. 162 cases were sorted into GOOD group, 45 cases into MODERATE group and 137 cases into BAD group.
  • FIGS. 3 , 4 and 5 show scatter plots of discriminant scores of 162 cases sorted into GOOD group, 45 cases sorted into MODERATE group, and 137 cases sorted into BAD group, respectively.
  • 162 cases sorted in GOOD group are divided into three groups based on X-axis value, and an analysis directed toward T-cell immunity was performed for cell-count data of 54 cases with low X-axis values.
  • Tc*DR lymphocyte A multiple regression analysis was performed using Tc*DR lymphocyte as objective variable, and CD3-positive lymphocyte, CD4-positive lymphocyte, CD8-positive lymphocyte, CD20*DR lymphocyte, Th ⁇ lymphocyte, Th ⁇ 2 lymphocyte, Th+2 lymphocyte, Act.Th1 lymphocyte, Act.Th2 lymphocyte, Ti*DR lymphocyte, Ti ⁇ lymphocyte, Ti ⁇ 2 lymphocyte, Ti+2 lymphocyte, Tc ⁇ lymphocyte, Tc+ lymphocyte, Ts*DR lymphocyte, Ts ⁇ lymphocyte, Ts+ lymphocyte, NK cell, NKT cell, N3+ cell, monocyte, basophil, eosinophil and neutrophil as explanatory variables. The contribution ratio was 96.473%.
  • the standard partial regression coefficients of 25 types of immunocompetent cells obtained by multiple regression analysis are shown in Table 3.
  • the standard partial regression coefficients of the immunocompetent cells obtained in this analysis were sorted in descending order according to their absolute values. Namely, in descending order from the highest absolute value: CD4-positive lymphocyte, Th ⁇ lymphocyte, Ti+2 lymphocyte, Ts*DR lymphocyte, Th ⁇ 2 lymphocyte, CD3-positive lymphocyte, Ti ⁇ 2 lymphocyte, Th+2 lymphocyte, Tc+ lymphocyte, N3+ cell, basophil, Ti ⁇ lymphocyte, monocyte, CD8-positive lymphocyte, CD20*DR lymphocyte, Tc ⁇ lymphocyte, NKT cell, NK cell, Act.Th2 lymphocyte, Act.Th1 lymphocyte, eosinophil, Ts ⁇ lymphocyte, Ts+ lymphocyte, neutrophil and Ti*DR lymphocyte.
  • the percentage of the influence degree was reflected to the area of a circle to generate an immunodynamics chart.
  • X denotes an influence degree below 0.00785%
  • ⁇ denotes the influence degree at or above 0.00785% and less than 0.0314%.
  • the generated immunodynamics chart is shown in FIG. 6 .
  • Anti-tumor effect is generally exerted as follows.
  • An antigen is loaded by an antigen-presenting cell (such as monocytes/macrophages) onto an MHC (Major Histocompatibility Complex) Class II molecule, presented to MHC Class II molecules on Act.Th1 lymphocyte.
  • Act.Th1 lymphocyte produces cytokines, etc. based on information of the antigen, promoting activation of activated cytotoxic T cells (Tc*DR), and at the same time presents the cancer- (tumor-) specific antigen on MHC Class I, thereby exerting anti-tumor effect. Therefore, in order to obtain a persistent anti-tumor effect, it is necessary that Monocyte->Act.Th1->Tc*DR pathway (T-cellular antigen recognition mechanism (TARM)) has been established.
  • TARM T-cellular antigen recognition mechanism
  • Act.Th1 is in negative relationship to Tc*DR and the pathway from Act.Th1 to Tc*DR has been disrupted. Thus, no anti-tumor effect can be expected.
  • Activation of TARM can be achieved by therapies for stimulating the pathway from monocyte to Act.Th1 by dendritic cell vaccine therapy, or alternatively by administrating interleukin-1 ⁇ (IL-1 ⁇ ) inhibitor (e.g., canakinumab, etc.) or functional foods or supplements such as fungal glycoproteins.
  • IL-1 ⁇ interleukin-1 ⁇
  • therapies of enhancing Tc*DR by activating Act.Th1 using interferon a, etc. can also be employed.
  • Ts*DR is at a level as high as 13.385%
  • the suppressing of Ts*DR using monoclonal antibodies, etc. would relieve Tc*DR from the suppression by Ts*DR and successfully activate/enhance CD3->CD8->Tc ⁇ ->Tc+->Tc*DR pathway, which might in turn open the TARM pathway.
  • IL-2 interleukin-2
  • helper system which might in turn open the TARM pathway.
  • Th+2 Active Regulatory T-helper Cells (Th+2) which serve in immunosuppression is at a slightly high level as 0.962%, suppressing them with an antibody medicine such as ipilimumab (Trade name: Yervoy®) and mogamulizumab would relieve the antigen-presenting cells of the monocyte/macrophage system, which might bring TARM to function.
  • Th+2 Active Regulatory T-helper Cells
  • CD20*DR lymphocyte goes through Monocyte->Act.Th2->CD20*DR pathway (B-cellular Antigen Recognition Mechanism (BARM)) to produce antigens in cancer (tumor) antigen-dependent manner, whereas NK cell and NKT cell exert an antibody-dependent cellular cytotoxicity (ADCC).
  • BARM B-cellular Antigen Recognition Mechanism
  • 162 cases sorted into GOOD group are divided into three groups based on X-axis value, and an analysis directed toward T-cell immunity was performed for cell-count data of 54 cases that had middle X-axis values in a similar way as in GOOD/lower X-axis group/T-cell immunity.
  • the influence degrees were calculated and an immunodynamics chart was generated.
  • the generated immunodynamics chart is shown in FIG. 7 .
  • TARM and BARM have been established. Note that, unlike FIG. 6 , differentiation and proliferation are stagnated at CD8, and the pathway from CD8 to Tc*DR has been disrupted. Possible treatments include activation/enhancement of CD3->CD8->Tc ⁇ ->Tc+->Tc*DR pathway by 1L-2 administration, etc. Moreover, monocyte/macrophage system is at an extremely low level as 0.007%, which also needs to be activated. Th+2 is at a low level and it therefore does not need to be suppressed. Ts*DR is at a level as high as 13.324, and therefore, in case if there is no improvement from the aforementioned treatment, a therapy for suppressing Ts*DR with antibody medicine may be employed.
  • 162 cases sorted in GOOD group are divided into three groups based on X-axis value, and an analysis directed toward NK cell was performed for cell-count data of 54 cases that had high X-axis values.
  • NK cell A multiple regression analysis was performed using NK cell as objective variable, and CD3-positive lymphocyte, CD4-positive lymphocyte, CD8-positive lymphocyte, CD20*DR lymphocyte, Th ⁇ lymphocyte, Th ⁇ 2 lymphocyte, Th+2 lymphocyte, Act.Th1 lymphocyte, Act.Th2 lymphocyte, Ti*DR lymphocyte, Ti ⁇ lymphocyte, Ti ⁇ 2 lymphocyte, Ti+2 lymphocyte, Tc ⁇ lymphocyte, Tc+ lymphocyte, Tc*DR lymphocyte, Ts*DR lymphocyte, Ts ⁇ lymphocyte, Ts+ lymphocyte, NKT cell, N3+ cell, monocyte, basophil, eosinophil and neutrophil as explanatory variables.
  • the standard partial regression coefficients of the immunocompetent cells obtained in this analysis were ranked in descending order according to their absolute values, and a multiple regression analysis using NK cell as objective variable was repeatedly performed in similar way as in GOOD/lower X-axis group/T-cell immunity, the influence degrees were calculated for all immunocompetent cells and an immunodynamics chart was generated.
  • the generated immunodynamics chart is shown in FIG. 8 .
  • TARM has been established, Tc*DR is at a level as low as 0.172%, and it is necessary to activate/enhance the pathway from CD8 to Tc*DR with IL-2 administration, etc. Namely, it can be said that this immune condition is just appropriate for applying NK-cell adoptive immunotherapy. Because BARM has also been established and ADCC is expected, anti-tumor immunity can be maintained and continued by activating TARM and BARM and enhancing NK cells.
  • the influence degrees were calculated and an immunodynamics chart was generated.
  • the generated immunodynamics chart is shown in FIG. 9 .
  • NK-cell adoptive immunotherapy is considered to be promising.
  • TARM has been established though being weak. However, the differentiation/activation/enhancement pathway has been disrupted at CD3, and in this case, no effect can be expected by carrying out dendritic cell vaccine therapy.
  • the influence degree of CD3 is 94.528%, and thus the influence degree of pathways for other immunocompetent cells including granulocyte system are 5.471%, which is only approx. 5%.
  • Treatment may include dissolving of the stagnation at CD3 by IL-2 administration, etc.
  • CD20*DR is at a level as low as 0.010%, and neither antigen production effect nor ADCC can be expected.
  • CD20*DR lymphocyte as objective variable, and CD3-positive lymphocyte, CD4-positive lymphocyte, CD8-positive lymphocyte, Th ⁇ lymphocyte, Th ⁇ 2 lymphocyte, Th+2 lymphocyte, Act.Th1 lymphocyte, Act.Th2 lymphocyte, Ti*DR lymphocyte, Ti ⁇ lymphocyte, Ti ⁇ 2 lymphocyte, Ti+2 lymphocyte, Tc ⁇ lymphocyte, Tc+ lymphocyte, Tc*DR lymphocyte, Ts*DR lymphocyte, Ts ⁇ lymphocyte, Ts+ lymphocyte, NK cell, NKT cell, N3+ cell, monocyte, basophil, eosinophil and neutrophil as explanatory variables.
  • the standard partial regression coefficients of the immunocompetent cells obtained in this analysis were ranked in descending order according to their absolute values, and a multiple regression analysis using CD20*DR lymphocyte as objective variable was repeatedly performed in similar way as in GOOD/lower X-axis group/T-cell immunity, and the influence degrees were calculated for all immunocompetent cells and an immunodynamics chart was generated.
  • the generated immunodynamics chart is shown in FIG. 11 .
  • the standard partial regression coefficients of the immunocompetent cells obtained in this analysis were ranked in descending order according to their absolute values, and a multiple regression analysis using basophil as objective variable was repeatedly performed in similar way as in GOOD/lower X-axis group/T-cell immunity, and the influence degrees were calculated for all immunocompetent cells and an immunodynamics chart was generated.
  • the generated immunodynamics chart is shown in FIG. 12 .
  • An immunodynamics chart directed to basophil shows an immunity related to immediate allergy, etc.
  • Tc*DR is in a negative relationship to basophil and the pathway has been disrupted.
  • a multiple regression analysis was performed using eosinophil as objective variable, and CD3-positive lymphocyte, CD4-positive lymphocyte, CD8-positive lymphocyte, CD20*DR lymphocyte, Th ⁇ lymphocyte, Th ⁇ 2 lymphocyte, Th+2 lymphocyte, Act.Th1 lymphocyte, Act.Th2 lymphocyte, Ti*DR lymphocyte, Ti ⁇ lymphocyte, Ti ⁇ 2 lymphocyte, Ti+2 lymphocyte, Tc ⁇ lymphocyte, Tc+ lymphocyte, Tc*DR lymphocyte, Ts*DR lymphocyte, Ts ⁇ lymphocyte, Ts+ lymphocyte, NK cell, NKT cell, N3+ cell, monocyte, basophil and neutrophil as explanatory variables.
  • the standard partial regression coefficients of the immunocompetent cells obtained in this analysis were ranked in descending order according to their absolute values, and a multiple regression analysis using eosinophil as objective variable was repeatedly performed in similar way as in GOOD/lower X-axis group/T-cell immunity, and the influence degrees were calculated for all immunocompetent cells and an immunodynamics chart was generated.
  • the generated immunodynamics chart is shown in FIG. 13 .
  • Tc*DR is in a negative relationship to eosinophil and the pathway has been disrupted.
  • a multiple regression analysis was performed using neutrophil as objective variable, and CD3-positive lymphocyte, CD4-positive lymphocyte, CD8-positive lymphocyte, CD20*DR lymphocyte, Th ⁇ lymphocyte, Th ⁇ 2 lymphocyte, Th+2 lymphocyte, Act.Th1 lymphocyte, Act.Th2 lymphocyte, Ti*DR lymphocyte, Ti ⁇ lymphocyte, Ti ⁇ 2 lymphocyte, Ti+2 lymphocyte, Tc ⁇ lymphocyte, Tc+ lymphocyte, Tc*DR lymphocyte, Ts*DR lymphocyte, Ts ⁇ lymphocyte, Ts+ lymphocyte, NK cell, NKT cell, N3+ cell, monocyte, basophil and eosinophil as explanatory variables.
  • the standard partial regression coefficients of the immunocompetent cells obtained in this analysis were ranked in descending order according to their absolute values, and a multiple regression analysis using neutrophil as objective variable was repeatedly performed in similar way as in GOOD/lower X-axis group/T-cell immunity, and the influence degrees were calculated for all immunocompetent cells and an immunodynamics chart was generated.
  • the generated immunodynamics chart is shown in FIG. 14 .
  • T-cell immunity anti-cancer immunity
  • TARM has barely been maintained, though Tc*DR is 0.000% and has been completely obstructed.
  • Tc*DR is in negative relationship to neutrophil, and in this case, the anti-tumor effect by neutrophils such as with fractalkines can hardly be expected.
  • Ts*DR Ts*DR
  • Ts*DR T-cell immunity
  • therapies include a method of suppressing Ts*DR with monoclonal antibodies, NK-cell adoptive immunotherapy or NKT-cell adoptive immunotherapy may also be promising in some cases.
  • ADCC activity may also be expected. Note that when using an immune checkpoint inhibitor, it is necessary to keep monitoring and observing the dynamics such that B-cell immunity will not become dominant.
  • NKT cell A multiple regression analysis was performed using NKT cell as objective variable, and CD3-positive lymphocyte, CD4-positive lymphocyte, CD8-positive lymphocyte, CD20*DR lymphocyte, Th ⁇ lymphocyte, Th ⁇ 2 lymphocyte, Th+2 lymphocyte, Act.Th1 lymphocyte, Act.Th2 lymphocyte, Ti*DR lymphocyte, Ti ⁇ lymphocyte, Ti ⁇ 2 lymphocyte, Ti+2 lymphocyte, Tc ⁇ lymphocyte, Tc+ lymphocyte, Tc*DR lymphocyte, Ts*DR lymphocyte, Ts ⁇ lymphocyte, Ts+ lymphocyte, NK cell, N3+ cell, monocyte, basophil, eosinophil and neutrophil as explanatory variables.
  • the standard partial regression coefficients of the immunocompetent cells obtained in this analysis were ranked in descending order according to their absolute values, a multiple regression analysis using NKT cell as objective variable was repeatedly performed in similar way as in GOOD/lower X-axis group/T-cell immunity, and the influence degrees were calculated for all immunocompetent cells and an immunodynamics chart was generated.
  • the generated immunodynamics chart is shown in FIG. 22 .
  • TARM nor BARM have been established. There is stagnation and disruption at CD4, which should be dissolved by IL-2 administration, etc. Although there is a possibility that TARM and BARM will be recovered by NK-cell adoptive immunotherapy, this is not an appropriate therapy in the light of the immunodynamics chart.
  • the influence degrees were calculated and an immunodynamics chart was generated. The generated immunodynamics chart is shown in FIG. 25 .
  • TARM has been established, there is significant stagnation at CD8. First of all, this stagnation should be improved by IL-2 administration, etc. Tc*DR is in positive relationship to NKT and is maintained. Since BARM has not been established, no ADCC activity can be expected.
  • Act.Th2 is dominant (Act.Th1 (0.001%) ⁇ Act.Th2 (0.020%)), Act.Th2->CD20*DR->NKT pathway has been disrupted and thus there is no need to be concerned about an autoimmunity-like side effect. Still, a discreet administration is desired when carrying out immunotherapy using an immune checkpoint inhibitor, etc. Monitoring by an immunodynamics chart monitor will be necessary.
  • TARM has barely been established, but there is significant stagnation at CD4. It is presumed that by relieving this stagnation by IL-2 administration, etc., the helper system will differentiate, proliferate or be enhanced, and the immunity will smoothly be turn around.
  • Act.Th2 is dominant (Act.Th1 (0.001%) ⁇ Act.Th2 (0.015%))
  • Act.Th2->CD20*DR pathway has been disrupted and thus there is no need to be concerned about an autoimmunity-like side effect.
  • monitoring by an immunodynamics chart monitor will be necessary.
  • the influence degrees were calculated and an immunodynamics chart was generated. The generated immunodynamics chart is shown in FIG. 29 .
  • TARM nor BARM have been established. Moreover, there is significant stagnation at CD04. It is essential to dissolve this stagnation by IL-2 administration, etc. to promote differentiation and proliferation of helper T cells. Since Ts*DR is at a considerably high level (17.621%), immunotherapy for suppressing it is also promising.
  • TARM and BARM have been established, and NKT activity and ADCC activity have also been established.
  • NKT activity and ADCC activity have also been established.
  • immunity will be more effective by any therapy for dissolving the stagnation of Ti*DR and promoting differentiation and proliferation of helper lymphocytes. It is also possible that Ti*DR will be suppressed by NK-cell adoptive immunotherapy.
  • Th1 is dominant (Act.Th1 (7.431%)>Act.Th2 (0.065%)), there is presumably no concern about side effects.
  • BARM has been established, whereas TARM has not. Because BARM has been established, it is necessary to be careful about a side effect which may be caused by using an immune checkpoint inhibitor.
  • Tc*DR lymphocyte as objective variable
  • Th17+lymphocyte CD3-positive lymphocyte, CD4-positive lymphocyte, CD8-positive lymphocyte, CD20*DR lymphocyte, Th ⁇ lymphocyte, Th ⁇ 2 lymphocyte, Th+2 lymphocyte, Act.Th1 lymphocyte, Act.Th2 lymphocyte, Ti*DR lymphocyte, Ti ⁇ lymphocyte, Ti ⁇ 2 lymphocyte, Ti+2 lymphocyte, Tc ⁇ lymphocyte, Tc+ lymphocyte, Ts*DR lymphocyte, Ts ⁇ lymphocyte, Ts+lymphocyte, NK cell, NKT cell, N3+ cell, monocyte, basophil, eosinophil and neutrophil as explanatory variables.
  • the standard partial regression coefficients of the immunocompetent cells obtained in this analysis were ranked in descending order according to their absolute values, a multiple regression analysis using Tc*DR lymphocyte as objective variable was repeatedly performed in similar way as in GOOD/lower X-axis group/T-cell immunity, and the influence degrees were calculated for all immunocompetent cells and an immunodynamics chart was generated.
  • the generated immunodynamics chart is shown in FIG. 34 .
  • TARM has been established, whereas BARM has not.
  • therapy such as administering a cytokine such as IL-2 can be considered.
  • cytokine such as IL-2
  • the next therapeutic means shall be considered.
  • Monocyte->Th17+->Tc*DR pathway has been established, which is weak but still contributing to anti-cancer (anti-tumor) immunity.
  • the influence degree of neutrophil is as low as 0.013% and it may have a low influence.
  • interleukin-17A/F (1L-17A/F), etc. is produced by being stimulated by various treatment such as fractalkines (either administered or produced in the body), and a pathway of:
  • Tc*DR a differentiation, activation or proliferation towards Tc*DR
  • an enhancement of anti-cancer (anti-tumor) effect can be expected.
  • a multiple regression analysis was performed for the cell-count data of 27 cases using CD20*DR lymphocyte as objective variable, and Th17+ lymphocyte, CD3-positive lymphocyte, CD4-positive lymphocyte, CD8-positive lymphocyte, Th ⁇ lymphocyte, Th ⁇ 2 lymphocyte, Th+2 lymphocyte, Act.Th1 lymphocyte, Act.Th2 lymphocyte, Ti*DR lymphocyte, Ti ⁇ lymphocyte, Ti ⁇ 2 lymphocyte, Ti+2 lymphocyte, Tc ⁇ lymphocyte, Tc+ lymphocyte, Tc*DR lymphocyte, Ts*DR lymphocyte, Ts ⁇ lymphocyte, Ts+ lymphocyte, NK cell, NKT cell, N3+ cell, monocyte, basophil, eosinophil and neutrophil as explanatory variables.
  • the standard partial regression coefficients of the immunocompetent cells obtained in this analysis were ranked in descending order according to their absolute values, a multiple regression analysis using CD20*DR lymphocyte as objective variable was repeatedly performed in similar way as in GOOD/lower X-axis group/T-cell immunity, and the influence degrees were calculated for all immunocompetent cells and an immunodynamics chart was generated.
  • the generated immunodynamics chart is shown in FIG. 35 .
  • helper T cells There is stagnation of differentiation and proliferation at CD4. Although the pathways of helper T cells are open, they are hindered and tapering off. TARM has barely been established.
  • T-cellular antigen recognition mechanism by interferon ⁇ , dendritic cell vaccine therapy, or fungal supplements for enhancing Tc*DR, or to carry out immunotherapy for activating and enhancing CD3->CD8->Tc ⁇ ->Tc+->Tc*DR pathway by 1L-2 or immune checkpoint inhibitors, etc.
  • Th17+ lymphocyte is 0.000% and extremely low, and is in a negative relationship with Th17+, the possibility of developing an allergic or autoimmunity-like side effect is low, with very little concern for such side effects.
  • Neutrophil->Th17+->CD20*DR pathway may be activated and the side effects such as fever or allergic skin disorders may be developed. Therefore, a similar strict observation is essential.
  • basophil is at relatively high level as 1.662%, which may cause an unexpected immediate allergic response. Therefore, immunotherapy should be carried out with discretion under a sufficient observation. If the influence degree of basophil towards Act.Th2 is further increased by a treatment, the treatment must be stopped.
  • the standard partial regression coefficients of the immunocompetent cells obtained in this analysis were ranked in descending order according to their absolute values, a multiple regression analysis using NKT cell as objective variable was repeatedly performed in similar way as in GOOD/lower X-axis group/T-cell immunity, and the influence degrees were calculated for all immunocompetent cells and an immunodynamics chart was generated.
  • the generated immunodynamics chart is shown in FIG. 36 .
  • Tc*DR In order to bring Tc*DR to differentiate, be activated or proliferate to enhance anti-tumor immunity, it is necessary to enhance the pathway towards Tc*DR by, e.g., administering ⁇ -galactosylceramide ( ⁇ -GalCer) or NKT cell-activating adoptive immunotherapy.
  • ⁇ -GalCer ⁇ -galactosylceramide
  • NKT cell-activating adoptive immunotherapy e.g., administering ⁇ -galactosylceramide ( ⁇ -GalCer) or NKT cell-activating adoptive immunotherapy.
  • the influence degree of basophil is slightly high as 0.987%, and there is a concern about development of immediate allergy which needs to be noted. If the influence degree of basophil is increased by a treatment, it is necessary to consider stopping or discontinuing the treatment.
  • n 28/NK Cell
  • the standard partial regression coefficients of the immunocompetent cells obtained in this analysis were ranked in descending order according to their absolute values, a multiple regression analysis using NK cell as objective variable was repeatedly performed in similar way as in GOOD/lower X-axis group/T-cell immunity, and the influence degrees were calculated for all immunocompetent cells and an immunodynamics chart was generated.
  • the generated immunodynamics chart is shown in FIG. 37 .
  • Act.Th2 is dominant (Act.Th1 (0.121%) ⁇ Act.Th2 (2.142%)), and thus it is important to take strict care not to facilitate B-cell antigen-producing immunity and thereby cause an onset of an allergic or autoimmunity-like disease. To this end, it becomes essential to monitor immunodynamics.
  • basophil is in positive relationship and the influence degree is increased, a special care is required because there is a concern for development of immediate allergic reaction.
  • the generated immunodynamics chart is shown in FIG. 38 .
  • a immunodynamics chart directed to basophil is an essential immunodynamics chart, because any severe allergic side effect can be predicted by generating it.
  • Monocyte->17+->Basophil pathway are disrupted, and thus there would be very little risk of an allergic reaction being developed.
  • Th17+lymphocyte CD3-positive lymphocyte, CD4-positive lymphocyte, CD8-positive lymphocyte, CD20*DR lymphocyte, Th ⁇ lymphocyte, Th ⁇ 2 lymphocyte, Th+2 lymphocyte, Act.Th1 lymphocyte, Act.Th2 lymphocyte, Ti*DR lymphocyte, Ti ⁇ lymphocyte, Ti ⁇ 2 lymphocyte, Ti+2 lymphocyte, Tc ⁇ lymphocyte, Tc+ lymphocyte, Tc*DR lymphocyte, Ts*DR lymphocyte, Ts ⁇ lymphocyte, Ts+ lymphocyte, NK cell, NKT cell, N3+ cell, monocyte, basophil and neutrophil as explanatory variables.
  • the generated immunodynamics chart is shown in FIG. 39 .
  • Th+2 Activated regulatory T cell
  • Th+2-suppressing agent such as ipilimumab (Trade name: Yervoy®) while taking sufficient care about following points:
  • Th17+ is poorly involved.
  • n 27/Neutrophil
  • a multiple regression analysis was performed the cell-count data of 27 cases using neutrophil as objective variable Th17+ lymphocyte, CD3-positive lymphocyte, CD4-positive lymphocyte, CD8-positive lymphocyte, CD20*DR lymphocyte, Th ⁇ lymphocyte, Th ⁇ 2 lymphocyte, Th+2 lymphocyte, Act.Th1 lymphocyte, Act.Th2 lymphocyte, Ti*DR lymphocyte, Ti ⁇ lymphocyte, Ti ⁇ 2 lymphocyte, Ti+2 lymphocyte, Tc ⁇ lymphocyte, Tc+ lymphocyte, Tc*DR lymphocyte, Ts*DR lymphocyte, Ts ⁇ lymphocyte, Ts+ lymphocyte, NK cell, NKT cell, N3+ cell, monocyte, basophil and eosinophil as explanatory variables.
  • the generated immunodynamics chart is shown in FIG. 40 .
  • B-cell immunity (Monocyte->Act.Th2->CD20*DR), which is a Th2-system, is open, and CD20*DR is so far in negative relationship to neutrophil, and thus there seems no issue of side effect.
  • side effects e.g., inflammatory autoimmune diseases
  • monitoring by an immunodynamics chart is essential. In pathways in which Th17+ is involved, Th17+ is in negative relationship to neutrophil, and thus there seems no concern about an inflammatory autoimmune dermatitis, etc. being developed.
  • TARM and BARM have been established, differentiation and proliferation are stagnated at CD8, and the pathway from CD8 to Tc*DR has been disrupted.
  • Treatments for this subject may include activation/enhancement of CD3->CD8->Tc ⁇ ->Tc+->Tc*DR pathway by IL-2 administration, etc.
  • Th+2 is at a low level and thus does not need to be suppressed.
  • Ts*DR is at a high level, and, if no improvement is achieved by the aforementioned treatment, Ts*DR-suppressing therapy with an antibody medicine can be considered.
  • NK activity index NK activity index
  • the NK activity index, NK ADCC-activity index, NKT activity index, ADCC activity index of NKT (NKT-ADCC-Activity Index), killer T-cell activity index (Killer Activity Index), and killer T-cell ADCC activity index (Killer-ADCC-Activity Index) were observed over time.
  • the results are shown in FIG. 41 .
  • NK activity index (NK-Activity-Index) was absent and a relapse was suspected.
  • NK activity index had been recovered, but killer T-cell activity index (Killer-Activity-Index) and killer T-cell ADCC activity index were absent in both two examinations.
  • NKT activity index (NKT-Activity-Index) was also absent in the beginning of October. Clinically, several locations containing small cauliflower-shaped tumor masses that were more evident than white spot were observed.
  • FIG. 42 shows transition of all indices
  • FIG. 43 shows transition of killer T-cell activity index and killer T-cell ADCC index in this subject
  • FIG. 44 shows transition of NK-cell activity index and NK-cell ADCC index in this subject
  • Fig, 45 shows transition of NKT-cell activity index and NKT-cell ADCC index in this subject.
  • PSA prostate-specific antigen
  • PSA value is elevated by 2.2 ng/ml for 1 gram of cancer (Lerner SE, Seay TM, Blute ML, Bergstralh EJ, Barrett D, Zincke H: Prostate specific antigen detected prostate cancer (clinical stage T1c): an interim analysis. J Urol 155:821-826, 1996), and the ultrasensitive measurement limit of PSA value is 0.001 ng/ml.
  • the subject has past history of hypertension and hypothyroidism, and has been taking Amlodin, Tanatril, and Thyradin S. Hormonal therapy with dihydrotestosterone (DHT) inhibitor started in 2009.
  • the inventor has been the attending physician since January, 2010. Immunotherapy has been considered since February, 2010, but has not been introduced, because the subject is categorized into GOOD group in the immunological examination in February 9, same year and seem to be in immunologically good condition regardless of an rising tendency of PSA value.
  • the subject fell into BAD group in the immunological examination in May 11, same year, and instructed to receive vaccine therapy. It became clear after two years that the subject fell into BAD group during the season of Japanese cedar pollinosis. After this, treatment for pollinosis has been given in combination. Furthermore, the subject was instructed to strictly follow diet cure.
  • the immunological condition went extremely worse and was categorized into BAD group. This is considered to be because of pollinosis. After that, the subject was instructed to take medicine for perennial allergy throughout a year. Basically, Allegra (fexofenadine) was taken. In the immunological examination on December 4, same year, the immunological condition transferred from GOOD to BAD group, indicating exacerbation of immunological condition. Therefore, the subject was instructed to avoid overeating and strictly keep abstinence.
  • NK-cell therapy By NK-cell therapy, PSA value decreased to 0.002, which is closed to measurement limit, i.e., 0.001.
  • the activity of NK cells was 96.2% (effector target ratio; 12:1) and the cultured NK-cell count (hereinafter, “cultured” means the lymphocytes collected from 40 ⁇ L of peripheral blood of the subject and cultured) was 2.49 billion and the cultured CD8+ ⁇ -T cell count was 4.024 billion on July 10, 2018, NK cell activity extremely decreased to 4.1% (effector target ratio; 12:1) on Aug. 10, 2018.
  • an increase of ⁇ -T cells was confirmed by a simple test. Therefore, NK-cell therapy was replaced with ⁇ -T cell therapy from Aug. 10, 2018.
  • the subject changed clinic.
  • Iatrogenic Hematemesis on Oct. 6, 2018 indicates an incidence of major bleeding (approximately 600 ml) and emergency operation after drinking small amount of alcohol on the day of gastric mucosal biopsy. Although the killer activity had successfully increased until this and further improvement had been expected, immunity dropped at once after this day. It is considered to be because of this incidence. The result of biopsy was not a cancer.
  • Killer T-cell activity index (Killer Cell Activity Index: Killer-AI) is in inverse correlation with PSA value, and thus when killer T-cell activity index is high, PSA value is low, while killer T-cell activity index is low or is not induced, PSA value is high.
  • killer T-cell activity index (Killer-Activity-Index) was 0.00978821
  • killer T-cell antibody-dependent cellular cytotoxicity index Killer-ADCC-Activity-Index
  • the treatment was changed to ⁇ -T cell adoptive immunotherapy from Aug. 10, 2018, in expectation of further enhancement and induction of killer activity.
  • the activity of the peripheral blood NK cells was 21%.
  • the cultured living cell count was 2.210 billion, and the activity of cultured NK cells was 95.5%, the cultured NK-cell count was 1.210 billion, the CD3+CD8+ ⁇ -T cell count was 0.890 billion.
  • the cultured living cell count was 3.470 billion
  • the activity of cultured NK cells was 96.5%
  • cultured NK-cell count was 2.110 billion
  • the CD3+CD8+ ⁇ cell count was 1.2 billion.
  • the cultured living cell count was 4.020 billion
  • the activity of cultured killer T-cells was 84.4%
  • the cultured NK-cell count was 0.670 billion
  • the CD3+CD8+ ⁇ cell count was 2.870 billion
  • the CD3+CD4+ ⁇ -T cell count was 0.380 billion.
  • the cultured living cell count was 9.750 billion, the activity of cultured killer T-cells was 73.7%, the cultured NK-cell count was 0.670 billion, the activity of peripheral blood NK cells (uncultured) was extremely decreased to 72%, the CD3+CD8+ ⁇ cell count was 8.290 billion, and the CD3+CD4+ ⁇ -T cell count was 0.310 billion.
  • the cultured living cell count was 8.730 billion
  • the activity of cultured killer T-cells was 91.1%
  • the cultured NK-cell count was 1.960 billion
  • the CD3+CD8+ ⁇ -T cell count was 5.450 billion
  • the CD3+CD4+ ⁇ -T cell count was 0.750 billion.
  • the cultured living cell count was 6.810 billion
  • the activity of cultured killer T-cells was 72.3%
  • the cultured NK-cell count was 1.360 billion
  • the CD3+CD8+ ⁇ -T cell count was 4.2 billion
  • the CD3+CD4+ ⁇ -T cell count was 0.790 billion. Note that the listing of indices is omitted.
  • NK-cell activity index (NK-Activity-Index) and NK-cell ADCC activity index (NK-ADCC-Activity-Index) did not appear before NK-cell therapy, but the treatment induced their appearance.
  • NK-cell activity index was as high as 2.397, and indicated 2.463 which was the highest value on Dec. 27, 2017.
  • PSA value decreased, indicating that they are in inverse correlation.
  • NKT-cell ADCC activity index decreased, in particular, from Aug. 10, 2018, and aforementioned killer T-cell ADCC activity index appeared on May 29, 2018, but has been disappeared since then. Therefore, ⁇ -T cell adoptive immunotherapy was considered to be appropriate, and the treatment was changed from NK-cell therapy to ⁇ -T cell adoptive immunotherapy. It is natural that NK-cell activity index and NK-cell ADCC activity index last appeared on Sep. 11, 2018 and disappeared until December 10, presumably due to the change in cell therapy.
  • NKT-cell activity index (NKT-Activity-Index) is in inverse correlation with PSA value in a similar way as the NK-cell activity index and the killer T-cell activity index.
  • NKT-cell activity index and NKT-cell ADCC activity index were both induced at the highest level. It is considered that PSA value was further decreased because of this. However, it last appeared in the beginning of October, 2018 and has not appeared thereafter.
  • the degree of tumor mass that can be destroyed by an immunocytic therapy can be predicted.
  • 1 gram of tumor mass contains 10 9 cancer cells.
  • 1 gram of tumor mass exist if there is an increase in PSA value by 2.2 ng/ml.
  • the number of cultured killer T-cells was 8.29 ⁇ 10 9
  • the activity of cultured killer T-cells was 73.7%
  • the killer T-cell activity index was 0.015619
  • the killer T-cell ADCC activity index was 0.053472.
  • PSA value 0.00795 ⁇ 2.2 ⁇ 0.0175 (ng/ml) indicating that the PSA value is predicted to decrease by 0.0175 ng/ml at a time.
  • Killer-Activity-Index was 1.168043, and no Killer-ADCC-Activity-Index appearance was induced or evoked.
  • the weight of tumor mass that was destroyed by NK-cell therapy can be predicted.
  • NK-cell ADCC activity index 10 9 (cells)/1 (g); wherein the activity of NK cells is introduced in decimal percentage, but not in integer percentage.
  • the number of cultured NK cells was 2.49 ⁇ 10 9
  • the activity of cultured NK cells (effector target ratio; 12:1) was 96.2%
  • NK-cell activity index was 2.102970
  • NK-cell ADCC activity index was 2.484033.
  • the weight of tumor mass that was destroyed by NKT-cell therapy can be predicted.
  • weight of tumor mass to be decreased (g) can be calculated by:
  • NKT-cell activity index the number of cultured NKT cells (cells) ⁇ 12 ⁇ the activity of cultured NKT-cells (effector target ratio; 12:1) ⁇ NKT-cell activity index ⁇ 10 9 (cells)/1 (g); wherein NKT-cell activity is introduced in decimal percentage, but not in integer percentage.
  • NKT-cell activity index was 0.23397 and the NKT-cell ADCC activity index was 0.000219.
  • NKT cells were cultured separately; although the activity was not measured, it can be predicted that:
  • this is converted into PSA value, a reduction of 0.00001825 ⁇ 2.2 ⁇ Z ⁇ Znkt (ng/ml) is predicted.
  • the sum of these, i.e., 0.019516 ⁇ Z ⁇ Znkt (g) will be destroyed.
  • the weight of tumor mass which would be destroyed will be the product of the number of grams predicted to be destroyed as mentioned above being multiplied by the number of days (i.e., 14-21).
  • an effective immunotherapy should be carried out appropriately and precisely such that each index will be increased.
  • An inappropriate immunotherapy might cause an exacerbation, and it is important and essential to keep monitoring immunodynamics.
  • the examination takes costs, it should be done if necessary, regardless of the costs.
  • the volume of tumor mass that would be destroyed can be presumed if data can be obtained for the respective activity of each lymphocyte in peripheral blood, without culturing each lymphocyte.
  • the volume of tumor mass of the subject's cancer that would be destroyed can be presumed by using cancer cells of the subject him/herself for the activity evaluation, not K562 cells which are usually used for activity evaluation.
  • the body weight ⁇ (1/13) ⁇ each peripheral blood cell count (killer ⁇ -T, NK or NKT) (/mm 3 ), the total number of effector cells (unit: 10 9 cells) is obtained.
  • the percentage of the activity of each effector cell can be examined, and the weight of tumor mass which would be destroyed can be predicted using indices obtained from an analysis of the chart of lymphocyte subset immunodynamics and calculating as mentioned above.
  • the subjects were 344 cases that were sorted into GOOD group, MODERATE group in Example 3.
  • a discriminant analysis was performed using 3 groups of GOOD, MODERATE and BAD groups as objective variables and 26 types of immunocompetent cells: CD3-positive lymphocyte, CD4-positive lymphocyte, CD8-positive lymphocyte, CD20*DR lymphocyte, Th ⁇ lymphocyte, Th ⁇ 2 lymphocyte, Th+2 lymphocyte, Act.Th1 lymphocyte, Act.Th2 lymphocyte, Ti*DR lymphocyte, Ti ⁇ lymphocyte, Ti ⁇ 2 lymphocyte, Ti+2 lymphocyte, Tc*DR lymphocyte, Tc ⁇ lymphocyte, Tc+ lymphocyte, Ts*DR lymphocyte, Ts ⁇ lymphocyte, Ts+ lymphocyte, NK cell, NKT cell, N3+ cell, monocyte, basophil, eosinophil and neutrophil as explanatory variables to give a discriminant function.
  • the present invention comprises methods of predicting prognosis of a subject from the cell-counts of multiple types of immunocompetent cells. For instance, for data cluster containing the values of levels of cancerous markers such as prostate-specific antigen (PSA) of individuals and data of the cell-count of each of multiple types of immunocompetent cells in blood collected from the individuals in a number that allows for the discriminant analysis, a multiple regression analysis is performed using PSA value as objective variable and the multiple types of immunocompetent cells are set as explanatory variables, subtracting the expected value from the observed value to give a residual value, and the individuals can be sorted into any number of groups in such a way that the smaller the residual value is, the better the expected prognosis would be.
  • PSA prostate-specific antigen
  • a discriminant function By performing a discriminant analysis using said groups as objective variables and the multiple types of immunocompetent cells are set as explanatory variables, a discriminant function can be obtained. By assigning the cell-count of the multiple types of immunocompetent cells of a subject into the discriminant function and calculating a discriminant score, the group to which the subject belongs can be determined and the prognosis can be predicted. Moreover, by obtaining immunodynamics-related information in each of the sorted groups, immunodynamics-related information of the subject is obtained, and therapy or prophylaxis according to the immunodynamics of the subject can be determined with that information.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Data Mining & Analysis (AREA)
  • Theoretical Computer Science (AREA)
  • Databases & Information Systems (AREA)
  • Biophysics (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioethics (AREA)
  • Physiology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
US16/958,167 2017-12-26 2018-12-25 Method, system, and program for supplying immunodynamics-related information Active 2040-02-23 US11959916B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JPJP2017-249877 2017-12-26
JP2017249877 2017-12-26
JP2017-249877 2017-12-26
PCT/JP2018/047438 WO2019131578A1 (ja) 2017-12-26 2018-12-25 免疫動態に関する情報を提供する方法、システムおよびプログラム

Publications (2)

Publication Number Publication Date
US20210231655A1 US20210231655A1 (en) 2021-07-29
US11959916B2 true US11959916B2 (en) 2024-04-16

Family

ID=67067307

Family Applications (1)

Application Number Title Priority Date Filing Date
US16/958,167 Active 2040-02-23 US11959916B2 (en) 2017-12-26 2018-12-25 Method, system, and program for supplying immunodynamics-related information

Country Status (5)

Country Link
US (1) US11959916B2 (ja)
EP (1) EP3734272A4 (ja)
JP (1) JP7329840B2 (ja)
CA (1) CA3086825A1 (ja)
WO (1) WO2019131578A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6796737B1 (ja) * 2020-06-02 2020-12-09 振武 曽 多項目自動血球計数装置

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991003736A1 (en) 1989-09-08 1991-03-21 Tamio Yamauchi Method of determining kinetics of immunity
US5639623A (en) 1989-09-08 1997-06-17 Yamauchi; Tamio Method of measuring immunokinetics
JP2568136Y2 (ja) 1992-03-30 1998-04-08 株式会社東海理化電機製作所 衛生器具の自動洗浄制御装置
WO2005004592A2 (en) 2003-07-30 2005-01-20 Institut Pasteur Transgenic mice having a human major histocompatibility complex (mhc) phenotype, experimental uses and applications
WO2007038758A2 (en) 2005-09-28 2007-04-05 Becton, Dickinson And Company Detection of lysophosphatidylcholine for prognosis or diagnosis of a systemic inflammatory condition
US20100042329A1 (en) * 2000-07-31 2010-02-18 Institute For Systems Biology Multiparameter analysis for predictive medicine
US20120195854A1 (en) * 2009-10-12 2012-08-02 Krensky Alan M Granulysin in immunotherapy
WO2015060779A1 (en) 2013-10-23 2015-04-30 Agnes Wold Method for decision support in diagnosis of neutropenic fever in hematology patients
WO2016027764A1 (ja) * 2014-08-19 2016-02-25 国立大学法人 岡山大学 免疫細胞の機能増強方法及び免疫細胞の多機能性評価方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2568136B2 (ja) * 1989-09-08 1996-12-25 民男 山内 免疫動態の測定法
WO2006004592A2 (en) 2004-05-28 2006-01-12 Mayo Foundation For Medical Education And Research Methods for autologous stem cell transplantation

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991003736A1 (en) 1989-09-08 1991-03-21 Tamio Yamauchi Method of determining kinetics of immunity
US5639623A (en) 1989-09-08 1997-06-17 Yamauchi; Tamio Method of measuring immunokinetics
JP2568136Y2 (ja) 1992-03-30 1998-04-08 株式会社東海理化電機製作所 衛生器具の自動洗浄制御装置
US20100042329A1 (en) * 2000-07-31 2010-02-18 Institute For Systems Biology Multiparameter analysis for predictive medicine
WO2005004592A2 (en) 2003-07-30 2005-01-20 Institut Pasteur Transgenic mice having a human major histocompatibility complex (mhc) phenotype, experimental uses and applications
WO2007038758A2 (en) 2005-09-28 2007-04-05 Becton, Dickinson And Company Detection of lysophosphatidylcholine for prognosis or diagnosis of a systemic inflammatory condition
US20120195854A1 (en) * 2009-10-12 2012-08-02 Krensky Alan M Granulysin in immunotherapy
WO2015060779A1 (en) 2013-10-23 2015-04-30 Agnes Wold Method for decision support in diagnosis of neutropenic fever in hematology patients
WO2016027764A1 (ja) * 2014-08-19 2016-02-25 国立大学法人 岡山大学 免疫細胞の機能増強方法及び免疫細胞の多機能性評価方法

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
Bishara et al. "Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer" European Journal of Obstetrics and Gynecology and Reproductive Biology 2008 138:71-75.
Extended European Search Report in EP 18897146.9 dated Dec. 15, 2021.
International Search Report and Written Opinion in PCT/JP2018/047438 dated Apr. 2, 2019 with English language translation.
Kobayashi et al. "Changes of Lymphocyte Subpopulation in Advanced Renal Cell Carcinoma Patients with Marked Response to α-Interferon Therapy" The Japanese journal of Urology 1994 85(9):1380-1387.
Nishimura et al. "A New Method to Determine Natural Killer Cell Activity Without Target Cells" http://dx.doi.org/10.5772/intechogen.71912 Chapter 9 2017 pp. 181-197.
Shinbu So et al. "Simple Lymphocyte Analytical Formulas to Monitor Change in Immunity" Japanese Journal of Clinical Laboratory Automation 2017 42(4) :470, 095.
Supram Hosuru Subramanya; Primary invasive laryngeal mycosis in an immunocompetent patient: a case report and clinicoepidemiological update; BMC Infectious Diseases 18 BioMed Central. (2018) (Year: 2018). *
Tsujino et al. "Review of Pre-treatment Peripheral Lymphocyte Subsets in Patients with Bladder Cancer" The Japanese Journal of Urology 1997 88 (2) :199, O-179.
Yamauchi et al. "Combined Treatment with Interferon-α and -γ1 land UFT for Metastatic Renal Cancer Based on Th1 and Th2 Theory: Immunological Study of the Anti-Tumor Effect According to Changes of Peripheral Blood Lymphocyte Subset and Monocyte Counts" Biotherapy 1998 12 (5) :731-735.
Yamauchi et al. "Discriminant Equations for Predictive Effectiveness of α-Interferon Treatment Against Metastatic Renal Cancer and Multiple Regression Equations for Predictive Survival Periods by Pre-treatment Counts of Peripheral Blood Lymphocyte Subsets and Monocytes" Biotherapy 1996 10(4):671-682.
Yamauchi et al. "Review on Immunotherapy Mainly Based on α-interferon for metastatic renal cell carcinoma: Relationship Between Antitumor Effectors and Survival Period as seen from Peripheral Blood Lymphocyte Subsets before Treatment" The Japanese Journal of Urology 1995 86(3) :636, P41.

Also Published As

Publication number Publication date
EP3734272A1 (en) 2020-11-04
JP7329840B2 (ja) 2023-08-21
US20210231655A1 (en) 2021-07-29
CA3086825A1 (en) 2019-07-04
WO2019131578A1 (ja) 2019-07-04
JPWO2019131578A1 (ja) 2021-01-21
EP3734272A4 (en) 2022-01-12

Similar Documents

Publication Publication Date Title
Bednarski et al. Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant
US11705220B2 (en) Systems and methods for identifying cancer treatments from normalized biomarker scores
Molgora et al. IL-1R8 is a checkpoint in NK cells regulating anti-tumour and anti-viral activity
Shapiro et al. Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse
Feng et al. IL-9 contributes to immunosuppression mediated by regulatory T cells and mast cells in B-cell non-hodgkin’s lymphoma
Wang et al. GARP-mediated active TGF-β1 induces bone marrow NK cell dysfunction in AML patients with early relapse post–allo-HSCT
CN111344568B (zh) 预测对免疫疗法的反应
Souri et al. HLA expression in uveal melanoma: an indicator of malignancy and a modifiable immunological target
Rimando et al. Flotetuzumab and other T-cell immunotherapies upregulate MHC class II expression on acute myeloid leukemia cells
US11959916B2 (en) Method, system, and program for supplying immunodynamics-related information
Tolstykh et al. Local bone-marrow exposure: how to interpret the data on stable chromosome aberrations in circulating lymphocytes?(some comments on the use of FISH method for dose reconstruction for Techa riverside Residents)
Pemmaraju et al. CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights
Kumar et al. Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses
Vershenya et al. Dose response for T-cell receptor (TCR) mutants in patients repeatedly treated with 131I for thyroid cancer
Feng et al. Anti-PD-1 therapy is beneficial for the survival of patients with oral squamous cell carcinoma
Ahmadi et al. In vitro–Generated MDSCs Reduce the Pregnancy Complications in an Abortion-Prone Murine Model
Stern et al. Deep dive into the immune response against murine mesothelioma permits design of novel anti-mesothelioma therapeutics
Chen et al. Integrating Single-Cell RNA-Seq and Bulk RNA-Seq to Explore the Key Role of Fatty Acid Metabolism in Breast Cancer
Daugherty-Lopes et al. BRAIN-METASTATIC MELANOMA MODELS UNCOVER IMMUNE AND MOLECULAR CORRELATES OF RESPONSE TO IMMUNOTHERAPY
Li et al. Research Article Efficacy and Safety of Pembrolizumab Monotherapy for Recurrent/Unresectable/Metastatic Oral Squamous Cell Carcinoma: A Single-Center Study in China
PETRA et al. Primary cutaneous diffuse large B-cell lymphoma, leg type–case report and literature review
Scaldaferri et al. 4CPS-152 Persistent cytopenia after CAR-T cells: treatment with eltrombopag: a case report
Aoki et al. Effective treatment of relapsed/refractory CD19‐positive B/T‐type mixed‐phenotype acute leukemia with blinatumomab: A case report
Van den Bossche et al. Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma—Protocol of the Immuno-MESODEC study
Panchal et al. Radiotherapy toxicity

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: MICROENTITY

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO MICRO (ORIGINAL EVENT CODE: MICR); ENTITY STATUS OF PATENT OWNER: MICROENTITY

STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE